Oric Pharmaceuticals【ORIC】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

8.96

買値

3.59

売値

10.60

出来高

0.00 日の範囲 0.00

6.33 52 週間の範囲 16.65

時価総額

632.28M

前日終値

8.96

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

420,837

発行済株式数

70,566,950

配当利回り

PER

-6.28

1 株当たり利益 (EPS)

-1.43

歳入

純利益

-100.7M

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company h... ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.oricpharma.com

本社

Wilmington, Delaware, USA

設立

Oric Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ORIC. The last closing price for Oric Pharmaceuticals was US$8.96. Over the last year, Oric Pharmaceuticals shares have traded in a share price range of US$ 6.33 to US$ 16.65.

Oric Pharmaceuticals currently has 70,566,950 shares in issue. The market capitalisation of Oric Pharmaceuticals is US$632.28 million. Oric Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.28.

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.775	-7.96096558808	9.735	10.21	8.935	210072	9.31685111	CS
4	-1.205	-11.854402361	10.165	10.61	8.105	334787	9.25862285	CS
12	-2.16	-19.4244604317	11.12	12.83	8.105	420837	9.68902617	CS
26	0.62	7.43405275779	8.34	12.83	6.33	492475	9.34257439	CS
52	0.33	3.82387022016	8.63	16.65	6.33	491801	10.19546281	CS
156	-5.69	-38.8395904437	14.65	17.26	2.36	442994	7.47800599	CS
260	-17.04	-65.5384615385	26	40.81	2.36	367410	11.5288755	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
PALIPalisade Bio Inc	US$ 2.95 (110.71%)	9.53M
DBVTDBV Technologies SA	US$ 4.34 (31.91%)	2.52M
AMPGAmplitech Group Inc	US$ 2.46 (27.46%)	10.18M
CTHRCharles and Colvard Ltd	US$ 1.96 (24.83%)	1.19M
WHLRWheeler Real Estate Investment Trust Inc	US$ 5.56 (24.66%)	1.07M
PNBKPatriot National Bancorp Inc	US$ 1.08 (-58.78%)	13
SPGCSacks Parente Golf Inc	US$ 0.58 (-58.57%)	41.23k
KROSKeros Therapeutics Inc	US$ 40.50 (-41.01%)	9.58k
AVGRAvinger Inc	US$ 0.50 (-39.02%)	36.36k
HEPAHepion Pharmaceuticals Inc	US$ 0.36 (-38.46%)	1
AMPGAmplitech Group Inc	US$ 2.47 (27.98%)	10.18M
PALIPalisade Bio Inc	US$ 2.94 (110.00%)	9.53M
RGTIRigetti Computing Inc	US$ 6.69 (-9.35%)	3.14M
RZLVRezolve AI Ltd	US$ 2.19 (10.05%)	2.91M
SVMHSRIVARU Holding Ltd	US$ 0.0273 (-0.36%)	2.71M